- Previous Close
244.00 - Open
244.00 - Bid 236.00 x --
- Ask 238.00 x --
- Day's Range
234.00 - 244.00 - 52 Week Range
81.00 - 1,545.00 - Volume
31,856,900 - Avg. Volume
106,661,003 - Market Cap (intraday)
2.652T - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-31.92 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 31, 2019
- 1y Target Est
--
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates in two segments, Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper. The company also provides skin care products comprising Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel; medical support products; over the counter, ethical, and sigma products in the areas of musculo-skeletal, cardiovascular and hematopoietic system, genito urinary system, and respiratory system, as well as mineral and health supplements, vitamins, and other consumer health products in the form of syrups, tablets, and capsules; and sanitizers and antiseptics. PT Pyridam Farma Tbk was founded in 1976 and is headquartered in Jakarta Selatan, Indonesia. PT Pyridam Farma Tbk is a subsidiary of Rejuve Global Investment Pte. Ltd.
www.pyfa.co.id1,193
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PYFA.JK
View MorePerformance Overview: PYFA.JK
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYFA.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYFA.JK
View MoreValuation Measures
Market Cap
2.74T
Enterprise Value
6.12T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.14
Price/Book (mrq)
2.29
Enterprise Value/Revenue
4.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.33%
Return on Assets (ttm)
-2.13%
Return on Equity (ttm)
-30.86%
Revenue (ttm)
1.34T
Net Income Avi to Common (ttm)
-246.24B
Diluted EPS (ttm)
-31.92
Balance Sheet and Cash Flow
Total Cash (mrq)
505.42B
Total Debt/Equity (mrq)
323.82%
Levered Free Cash Flow (ttm)
-465.92B